MedTrace Logo

D-cycloserine Augmented CBT for Panic Disorder

NCT01680107 · Status: TERMINATED · Phase: PHASE3 · Type: INTERVENTIONAL · Enrollment: 33

Last updated 2018-05-03

No results posted yet for this study

Summary

The purpose of this study is to determine whether d-cycloserine augments the clinical effects of exposure-based cognitive-behaviour therapy for panic disorder.

Conditions

  • Panic Disorder

Interventions

DRUG

d-cycloserine

DRUG

placebo

BEHAVIORAL

cognitive-behaviour therapy

Sponsors & Collaborators

Principal Investigators

  • Andrea Reinecke, PhD · University of Oxford

  • Catherine Harmer, PhD · University of Oxford

Study Design

Allocation
RANDOMIZED
Purpose
BASIC_SCIENCE
Masking
QUADRUPLE
Model
PARALLEL

Eligibility

Min Age
18 Years
Max Age
65 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2012-10-31
Primary Completion
2017-10-31
Completion
2018-04-30

Countries

  • United Kingdom

Study Locations

More Related Trials

Entities

Drugs
Companies

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT01680107 on ClinicalTrials.gov